Congress Asset Management Co. Cuts Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• Congress Asset Management Co. reduced its stake in Thermo Fisher Scientific by 3.1% in the second quarter, now holding 162,498 shares valued at approximately $65.9 million.
• Thermo Fisher Scientific reported a quarterly EPS of $5.36 for Q2, exceeding analysts' estimates, with revenue of $10.86 billion representing a 2.9% increase year-over-year.
• The company announced a quarterly dividend of $0.43 per share, reflecting an annualized yield of 0.4% based on its current stock price.

Congress Asset Management Co. lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 162,498 shares of the medical research company's stock after selling 5,251 shares during the quarter. Congress Asset Management Co.'s holdings in Thermo Fisher Scientific were worth $65,887,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. CBIZ Investment Advisory Services LLC lifted its position in Thermo Fisher Scientific by 137.5% in the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock valued at $28,000 after purchasing an additional 33 shares during the last quarter. Ameriflex Group Inc. bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $30,000. Anderson Financial Strategies LLC bought a new position in shares of Thermo Fisher Scientific during the first quarter valued at approximately $30,000. Keystone Global Partners LLC bought a new position in shares of Thermo Fisher Scientific during the first quarter valued at approximately $31,000. Finally, IMA Advisory Services Inc. bought a new position in shares of Thermo Fisher Scientific during the first quarter valued at approximately $35,000. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Trading Down 1.9%

Thermo Fisher Scientific stock opened at $459.34 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $623.77. The stock has a market capitalization of $173.45 billion, a PE ratio of 26.57, a price-to-earnings-growth ratio of 2.54 and a beta of 0.75. The business's fifty day moving average is $475.73 and its 200 day moving average is $448.37.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. During the same period last year, the firm posted $5.37 earnings per share. Thermo Fisher Scientific's revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is currently 9.95%.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the transaction, the chief executive officer owned 115,174 shares of the company's stock, valued at approximately $57,697,567.04. This represents a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. UBS Group upped their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research note on Thursday, July 24th. HSBC reaffirmed a "hold" rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Evercore ISI cut their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Raymond James Financial reissued an "outperform" rating and issued a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Finally, Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the stock an "outperform" rating in a research note on Tuesday, September 2nd. Sixteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $588.35.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.